Toward Greater Diversity in Psychedelic Science.
Psychiatric Services February 5, 2026 DOI: 10.1176/appi.ps.20250169 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Psychedelic-assisted therapy |
| Keywords | Cultural competence Drug treatment/psychopharmacology Psychedelics Racial-ethnic disparities Racism |
| Citations | 1 |
| Key findings | Racial-ethnic diversity is lacking in psychedelic science and efforts to increase representation remain insufficient. |
Abstract
Racial-ethnic diversity is lacking in psychedelic science. Efforts have been made to increase racial-ethnic representation among clinical trial participant populations, but much work remains. This column aims to describe this disparity, outline potential benefits of eliminating this disparity, and provide recommendations for achieving equity and justice within the research landscape of psychedelic treatments for mental disorders.
Comparable studies
Other narrative reviews on psychedelic-assisted therapy, most cited first.
Citations in the library
Cites 11
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacology December 1, 2011
- Global Street Food: la cocina de la calle Diseño interior 2009
- MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nature Medicine October 1, 2023
- Inclusion of people of color in psychedelic-assisted psychotherapy: a review of the literature BMC Psychiatry July 31, 2018
and 6 more in the library